MyFinsight
Home
Blog
About
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,505,739
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Cash acquired in acquisition of ...
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Accrued expenses
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-1,152,810
-2,257,890
Change in right-of-use assets
0
17,994
Impairment of right-of-use assets
0
108,759
Prepaid expenses
-45,984
-1,160
Lease liabilities
0
-4,925
Deposits
-1
-49,129
Accounts payable
176,463
339,199
Accrued expenses
-5,120
163,396
Other liabilities
79,795
709,665
Net cash used in operating activities
-855,688
-873,513
Cash acquired in acquisition of imgx
336,427
-
Net cash provided by investing activities
336,427
-
Proceeds from issuance of common stock, prefunded warrants and warrants, net
3,025,000
-
Proceeds from line of credit
0
700,000
Net cash provided by financing activities
3,025,000
700,000
Net (decrease) in cash, cash equivalents and restricted cash
2,505,739
-173,513
Cash and cash equivalents at beginning of period
184,992
-
Cash and cash equivalents at end of period
2,517,218
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock,...
$3,025,000
Cash acquired in
acquisition of imgx
$336,427
Net cash provided by
financing activities
$3,025,000
Net cash provided by
investing activities
$336,427
Net (decrease) in
cash, cash...
$2,505,739
Canceled cashflow
$855,688
Accounts payable
$176,463
Other liabilities
$79,795
Prepaid expenses
-$45,984
Deposits
-$1
Net cash used in
operating activities
-$855,688
Canceled cashflow
$302,243
Net loss
-$1,152,810
Accrued expenses
-$5,120
Buy us a coffee